Non disponible en dehors du Royaume-Uni et de l'Irlande
Biochem/physiol Actions
Target IC50: 18 µM against angiotensin converting enzyme
Cell permeable: no
Reversible: no
Product does not compete with ATP.
Primary TargetMMPs
General description
A hydroxamate-based inhibitor of matrix metalloproteinases and TACE (TNF-α convertase; ADAM17). Inhibits the activation-dependent shedding of L-selectin from neutrophils, eosinophils, and lymphocytes as well as phenylarsine oxide (PAO)-induced shedding in neutrophils. Also blocks the shedding of several cell surface proteins such as pro-TGF-α, IL-6 receptor α-subunit, and β-amyloid precursor protein. Reported to inhibit TNF-α release and impart protection against aspirin-induced gastric mucosal injury. Acts as a weak inhibitor of angiotensin converting enzyme (IC50 = 18 µM).
A hydroxamate-based inhibitor of MMPs and TACE. Inhibits the activation-induced shedding of L-selectin from neutrophils, eosinophils, and lymphocytes, as well as phenylarsine oxide (PAO)-induced shedding in neutrophils. Also acts as a weak inhibitor of angiotensin converting enzyme (IC50 = 18 µM). Also available as a 10 mM solution in H2O (Cat. No. 509612).
Legal Information
Manufactured exclusively by Peptides International, Louisville, Kentucky, USA.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Bennett, T.A., et al. 2000. J. Immunol.164, 4120.Fiorucci, S., et al. 1998. Aliment. Pharmacol. Ther.12, 1139.Hooper, N.M., et al. 1997. Biochem. J.321, 265.Parvathy, S., et al. 1997. Biochem. J. 327, 37.Arribas, J., et al. 1996. J. Biol. Chem.271, 11376.
Packaging
1 mg in Plastic ampoule
Packaged under inert gas
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Warning
Toxicity: Standard Handling (A)
Ce produit répond aux critères suivants pour être admissible aux récompenses suivantes :